Protective Efficacy of a Live Attenuated Vaccine against Argentine Hemorrhagic Fever | Zendy

Julio I. Maiztegui | Zendy; Kelly T. McKee | Zendy; Julio G. Barrera Oro | Zendy; Lee H. Harrison | Zendy; Paul Gibbs | Zendy; María Rosa Feuillade | Zendy; Delia Enría | Zendy; Ana M. Briggiler | Zendy; Silvana Levis | Zendy; Ana María Ambrosio | Zendy; Neal A. Halsey | Zendy; C. J. Peters | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Protective Efficacy of a Live Attenuated Vaccine against Argentine Hemorrhagic Fever

Author(s) -

Julio I. Maiztegui,

Kelly T. McKee,

Julio G. Barrera Oro,

Lee H. Harrison,

Paul Gibbs,

María Rosa Feuillade,

Delia Enría,

Ana M. Briggiler,

Silvana Levis,

Ana María Ambrosio,

Neal A. Halsey,

C. J. Peters

Publication year - 1998

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/514211

Subject(s) - junin virus , arenavirus , medicine , placebo , vaccine efficacy , vaccination , adverse effect , randomized controlled trial , virology , attenuated vaccine , immunology , lymphocytic choriomeningitis , biology , pathology , immune system , biochemistry , alternative medicine , virulence , gene , cd8

Argentine hemorrhagic fever (AHF), caused by the arenavirus Junin, is a major public health problem among agricultural workers in Argentina. A prospective, randomized, double-blind, placebo-controlled, efficacy trial of Candid 1, a live attenuated Junin virus vaccine, was conducted over two consecutive epidemic seasons among 6500 male agricultural workers in the AHF-endemic region. Twenty-three men developed laboratory-confirmed AHF during the study; 22 received placebo and 1 received vaccine (vaccine efficacy 95%; 95% confidence interval [CI], 82%-99%). Three additional subjects in each group developed laboratory-confirmed Junin virus infection associated with mild illnesses that did not fulfill the clinical case definition for AHF, yielding a protective efficacy for prevention of any illness associated with Junin virus infection of 84% (95% CI, 60%-94%). No serious adverse events were attributed to vaccination. Candid 1, the first vaccine for the prevention of illness caused by an arenavirus, is safe and highly efficacious.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research